GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer

Journal of Urology

Volumn 192, Issue 5, 2014, Pages 1542-1548

  Maldonado, Leonel ^a   Brait, Mariana ^a   Loyo, Myriam ^a   Sullenberger, Lauren ^a   Wang, Kevin ^a   Peskoe, Sarah B ^b   Rosenbaum, Eli ^a   Howard, Roslyn ^a   Toubaji, Antoun ^c   Albadine, Roula ^c   Netto, George J ^a,c   Hoque, Mohammad O ^a   Platz, Elizabeth A ^a,b   Sidransky, David ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

biological markers; glutathione S transferase pi; methylation; neoplasm recurrence, local; prostatic neoplasms

Indexed keywords

APC PROTEIN; CD146 ANTIGEN; CYCLIN D2; DNA; GLUTATHIONE PEROXIDASE 3; GLUTATHIONE TRANSFERASE P1; PROSTATE SPECIFIC ANTIGEN; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA 2; SINGLE STRANDED DNA BINDING PROTEIN; SINGLE STRANDED DNA BINDING PROTEIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CASE CONTROL STUDY; CONTROLLED STUDY; CPG ISLAND; DNA EXTRACTION; DNA METHYLATION; EARLY CANCER; GENETIC ASSOCIATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE BIOPSY; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; RECURRENCE RISK; RECURRENT DISEASE; CLINICAL TRIAL; FOLLOW UP; GENETICS; INCIDENCE; METABOLISM; MULTICENTER STUDY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; UNITED STATES;

DNA METHYLATION; DNA, NEOPLASM; FOLLOW-UP STUDIES; GLUTATHIONE S-TRANSFERASE PI; HUMANS; INCIDENCE; MALE; MARYLAND; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84906326131     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2014.04.082     Document Type: Article

References (30)

1. D.F. Gleason, and G.T. Mellinger Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging J Urol 111 1974 58
2. P.C. Albertsen, J.A. Hanley, and J. Fine 20-year outcomes following conservative management of clinically localized prostate cancer JAMA 293 2005 2095
3. J.R. Stark, S. Perner, and M.J. Stampfer Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27 2009 3459
4. J.L. Wright, C.A. Salinas, and D.W. Lin Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort J Urol 182 2009 2702
5. M.L. Gonzalgo, P.J. Bastian, and L.A. Mangold Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate Urology 67 2006 115
6. M. Han, A.W. Partin, and C.R. Pound Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience Urol Clin North Am 28 2001 555
7. J.G. Herman, and S.B. Baylin Gene silencing in cancer in association with promoter hypermethylation N Engl J Med 349 2003 2042
8. P.A. Jones, and S.B. Baylin The fundamental role of epigenetic events in cancer Nat Rev Genet 3 2002 415
9. M. Nakayama, M.L. Gonzalgo, and S. Yegnasubramanian GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer J Cell Biochem 91 2004 540
10. M. Nakayama, C.J. Bennett, and J.L. Hicks Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection Am J Pathol 163 2003 923
11. C. Jeronimo, H. Usadel, and R. Henrique Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma J Natl Cancer Inst 93 2001 1747
12. H. Enokida, H. Shiina, and S. Urakami Multigene methylation analysis for detection and staging of prostate cancer Clin Cancer Res 11 2005 6582
13. A. Toubaji, R. Albadine, and A.K. Meeker Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas Mod Pathol 24 2011 1511
14. A. Chaux, S.B. Peskoe, and N. Gonzalez-Roibon Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer Mod Pathol 25 2012 1543
15. M.O. Hoque, O. Topaloglu, and S. Begum Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects J Clin Oncol 23 2005 6569
16. P.J. Bastian, J. Ellinger, and L.C. Heukamp Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy Eur Urol 51 2007 665
17. E. Rosenbaum, M.O. Hoque, and Y. Cohen Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy Clin Cancer Res 11 2005 8321
18. D.K. Vanaja, M. Ehrich, and D. Van den Boom Hypermethylation of genes for diagnosis and risk stratification of prostate cancer Cancer Invest 27 2009 549
19. K. Woodson, K.J. O'Reilly, and D.E. Ward CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease Epigenetics 1 2006 183
20. P.J. Bastian, G.S. Palapattu, and X. Lin Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy Clin Cancer Res 11 2005 4037
21. M. Rouprêt, V. Hupertan, and J.W. Catto Promoter hypermethylation in circulating blood cells identifies prostate cancer progression Int J Cancer 122 2008 952
22. S. Mahapatra, E.W. Klee, and C.Y. Young Global methylation profiling for risk prediction of prostate cancer Clin Cancer Res 18 2012 2882
23. Y.P. Yu, G. Yu, and G. Tseng Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis Cancer Res 67 2007 8043
24. R. Henrique, V.L. Costa, and N. Cerveira Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer J Mol Med (Berl) 84 2006 911
25. L. Liu, K.J. Kron, and V.V. Pethe Association of tissue promoter methylation levels of APC, TGFbeta2, HOXD3 and RASSF1A with prostate cancer progression Int J Cancer 129 2011 2454
26. Y. Tokumaru, S.V. Harden, and D.I. Sun Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma Clin Cancer Res 10 2004 5518
27. E. Rosenbaum, S. Begum, and M. Brait AIM1 promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy Prostate 72 2012 1133
28. J.W. Liu, J.K. Nagpal, and C. Jeronimo Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer Prostate 68 2008 418
29. J.W. Liu, J.K. Nagpal, and W. Sun ssDNA-binding protein 2 is frequently hypermethylated and suppresses cell growth in human prostate cancer Clin Cancer Res 14 2008 3754
30. W.G. Nelson, A.M. De Marzo, and S. Yegnasubramanian Epigenetic alterations in human prostate cancers Endocrinology 150 2009 3991